Skip to Content

Join the 'Non-Small Cell Lung Cancer' group to help and get support from people like you.

Non-Small Cell Lung Cancer News

Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC

Takeda Announces FDA Accelerated Approval of Alunbrig (brigatinib)

Posted 10 hours ago by Drugs.com

Cambridge, Mass. and Osaka, Japan – April 28, 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that Alunbrig (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under Accelerated Approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Alunbrig, which previously received Breakthrough Therapy Designation from the FDA, is a once-daily oral therapy that may be taken with or without food. “In recent years, small molecule ALK inhibitors have revolutionized the treatment options fo ... Read more

Related support groups: Non-Small Cell Lung Cancer, Alunbrig, Brigatinib

Study Says Blood-Chromosome Test Predicts Lung Cancer's Return

Posted 2 days 19 hours ago by Drugs.com

WEDNESDAY, April 26, 2017 – Unstable chromosomes within lung cancer tumors increase the risk that the cancer will return after surgery, researchers report. The investigators said they used this new information to forecast the return of lung cancer long before standard tests could spot it. The findings were published April 26 in the New England Journal of Medicine and Nature. The Cancer Research UK-funded TRACERx study included 100 patients with non-small cell lung cancer. The study participants were followed from diagnosis, through surgery, to either cure or disease relapse. Patients with a high proportion of unstable chromosomes in their tumors had more than quadruple the risk of their cancer returning, or of dying from their disease, within two years, the findings showed. The study offers "new insights into how tumors evolve and evade treatment, a leading cause of cancer death," lead ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Diagnosis and Investigation

Drug Offers Some Hope for a Deadly Lung Cancer

Posted 4 Apr 2017 by Drugs.com

TUESDAY, April 4, 2017 – The cancer drug Opdivo (nivolumab) may offer hope of a longer life for some patients with advanced lung cancer, a new small study finds. Currently, only about 5 percent of patients with advanced non-small-cell lung cancer survive five years or more. But that rate rose to about 16 percent among a group taking Opdivo, researchers reported Monday. "For the first time we are reporting long-term survival for patients with advanced lung cancer," said lead researcher Dr. Julie Brahmer. Brahmer is an associate professor of oncology at the Johns Hopkins University Institute for Cancer Immunotherapy in Baltimore. Opdivo is an immunotherapy drug, which means it enlists the patient's own immune system to fight diseases such as cancer. "Immune therapy may play a role in almost any cancer. We are working to increase the response in lung cancer patients," Brahmer said. Opdivo ... Read more

Related support groups: Non-Small Cell Lung Cancer, Opdivo, Nivolumab

Tagrisso (osimertinib) Receives FDA Full Approval

Posted 3 Apr 2017 by Drugs.com

31 March 2017 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after an EGFR tyrosine kinase inhibitor (TKI) therapy. Tagrisso is the first and only approved medicine in the US indicated for NSCLC patients who have tested positive for the EGFR T790M mutation, and efficacy data suggest it may be a new standard of care for these patients. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “By following the science, we aim to turn lung cancer into a chronic, manageable disease for patients and this m ... Read more

Related support groups: Non-Small Cell Lung Cancer, Tagrisso, Osimertinib

Survival Continues to Improve for Most Cancers

Posted 31 Mar 2017 by Drugs.com

FRIDAY, March 31, 2017 – Overall cancer death rates in the United States continue to fall, but racial gaps persist, a new report says. Death rates fell between 2010 and 2014 for 11 of the 16 most common cancers in men and for 13 of the most common types in women, including lung, colon, prostate and breast cancers. However, death rates rose for cancers of the liver, pancreas and brain in men and for the liver and uterus in women. And improvements in cancer survival weren't equal for all Americans. "While this report found that five-year survival for most types of cancer improved among both blacks and whites over the past several decades, racial disparities for many common cancers have persisted, and they may have increased for prostate cancer and female breast cancer," said Dr. Lynne Penberthy. She's associate director of the U.S. National Cancer Institute's Surveillance Research ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic, Brain Tumor, Melanoma, Skin Cancer, Osteosarcoma, Pancreatic Cancer, Ovarian Cancer, Endometrial Cancer, Small Cell Lung Cancer, Breast Cancer - Adjuvant, Cervical Cancer, Bladder Cancer, Melanoma - Metastatic

Smoking Rates Drop After Global Tobacco Treaty

Posted 22 Mar 2017 by Drugs.com

WEDNESDAY, March 22, 2017 – After 180 countries agreed to a global tobacco control treaty in 2005, there was a 2.5 percent decrease in smoking worldwide during the next decade, a new study shows. All of the participating countries agreed to the World Health Organization Framework Convention on Tobacco Control (FCTC). Signing countries committed to introducing policies such as high tobacco taxes and smoke-free public spaces. They also agreed to warning labels, advertising bans, and support for smoking cessation services. "The study provides strong evidence that the FCTC has led to a significant increase in the implementation of tobacco control measures," said study co-author Geoffrey Fong, professor of psychology and health studies at the University of Waterloo in Canada. He and his colleagues reviewed data from 116 countries that signed the treaty and 10 that didn't. Overall, smoking ... Read more

Related support groups: Cancer, Smoking, Smoking Cessation, Nicotine, Lung Cancer, Non-Small Cell Lung Cancer, Nicorette, Nicoderm CQ, Small Cell Lung Cancer, Nicotrol Inhaler, Commit, Habitrol, Nicorette DS, Nicotrol NS, ProStep, Nicotrol TD, Nicorelief

Blood Test May Spot Lung Cancer's Return, Even Before Scans

Posted 20 Mar 2017 by Drugs.com

MONDAY, March 20, 2017 – A blood test can detect the return of lung cancer months before CT and PET scans, a new study suggests. The research included 48 adults with stage 2 or 3 locally advanced non-small cell lung cancer (NSCLC). The patients were aged 31 to 84. All were treated with chemotherapy and radiation. Blood samples were taken before treatment, during treatment, and at six different times during the two years following treatment. The blood samples were checked for increased levels of circulating tumor cells, the researchers said. The blood tests were able to detect lung cancer recurrence an average of six months before CT and PET scans, the investigators found. The study was presented March 16 at a meeting of the American Society for Radiation Oncology, in San Francisco. Research presented at meetings should be viewed as preliminary until published in a peer-reviewed ... Read more

Related support groups: Non-Small Cell Lung Cancer, Diagnosis and Investigation, Body Imaging

Gleevec Keeps a Leukemia in Check for More Than a Decade: Study

Posted 9 Mar 2017 by Drugs.com

WEDNESDAY, March 8, 2017 – The cancer drug Gleevec appears to keep chronic myeloid leukemia at bay a decade into treatment – with no signs of additional safety risks, a new study finds. Gleevec – known generically as imatinib – was hailed as a "wonder drug" when it was introduced in 2001 for treating chronic myeloid leukemia (CML). CML is a type of blood cancer that strikes about 5,000 Americans each year, according to the U.S. National Cancer Institute (NCI). Before Gleevec, a CML diagnosis "amounted to a death sentence," the institute said. Now, most cases can be controlled, with either Gleevec or related drugs that have been developed since then. The new findings offer more evidence that the early "hype" around Gleevec was correct, said lead researcher Dr. Andreas Hochhaus, of Jena University Hospital in Germany. Of more than 500 CML patients given Gleevec as their initial ... Read more

Related support groups: Leukemia, Chronic Myelogenous Leukemia (CML), Lung Cancer, Gleevec, Non-Small Cell Lung Cancer, Melanoma, Tasigna, Chronic Lymphocytic Leukemia (CLL), Sprycel, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Dasatinib, Imatinib, Nilotinib, Acute Lymphocytic Leukemia, Acute Myeloblastic Leukemia

Nasal Swab Shows Promise in Confirming Lung Cancers

Posted 27 Feb 2017 by Drugs.com

MONDAY, Feb. 27, 2017 – Lung cancer remains by far the leading cancer killer because it is so often caught too late. But researchers now say it may someday be possible to quickly confirm the disease after a CT scan, by using a simple nasal swab. The key is DNA-based "biomarkers" in the nasal passages that appear to reveal whether a lung lesion is cancerous or not. "Nasal gene expression [production] contains information about the presence of cancer," explained study co-author Marc Lenburg. He believes the nasal swab "might aid in lung cancer detection." The researchers said the test might help doctors spare some patients expensive and risky follow-up procedures. Lenburg is professor of medicine at Boston University and made his comments in a university news release. He and his colleagues published their findings Feb. 27 in the Journal of the National Cancer Institute. As the ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Respiratory Tract Disease, Diagnosis and Investigation

Cancer Survivors Gain From Web-Based Health Care

Posted 10 Feb 2017 by Drugs.com

FRIDAY, Feb. 10, 2017 – Online- and phone-based health care offers a number of benefits for cancer survivors, British researchers report. The new study looked at previous research on cancer survivors' experiences with online and phone health contacts – what the researchers call telehealth. The review found that patients liked the flexibility and convenience of this method of staying in touch with their care providers because they could do so in a familiar, comfortable setting and with minimum disruption to their lives. The perceived anonymity of telehealth reduced patients' sense of vulnerability and some said they were more comfortable raising concerns in this setting than in face-to-face appointments. Negative aspects of telehealth mentioned by patients included not being able to meet their health care providers in person, while other patients said they couldn't use the service due ... Read more

Related support groups: Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic, Brain Tumor, Skin Cancer, Ovarian Cancer, Small Cell Lung Cancer, Bladder Cancer, Cervical Cancer, Stomach Cancer, Head and Neck Cancer, Breast Cancer, Prevention, Testicular Cancer, Breast Cancer - Palliative, Zollinger-Ellison Syndrome, Wilms' Tumor, Solid Tumors

Too Few Current, Former Smokers Screened for Lung Cancer

Posted 2 Feb 2017 by Drugs.com

THURSDAY, Feb. 2, 2017 – Most current and former smokers in the United States don't get screened for lung cancer even though they're at increased risk for the deadly disease, a new study reveals. The findings highlight the need to educate doctors and at-risk patients about lung cancer screening, according to the American Cancer Society researchers. Their analysis of federal government data found that the proportion of eligible current and former smokers who underwent lung cancer screening in the past 12 months remained low – 3.3 percent in 2010 to 3.9 percent in 2015. The researchers calculated that of the 6.8 million current and former smokers eligible for lung cancer screening in 2015, only 262,700 received it. "The reasons for the low uptake in screening are probably varied, and likely include lack of knowledge among both smokers and doctors as to screening recommendations, as well ... Read more

Related support groups: Smoking, Smoking Cessation, Nicotine, Lung Cancer, Non-Small Cell Lung Cancer, Nicorette, Nicoderm CQ, Small Cell Lung Cancer, Nicotrol Inhaler, Commit, Habitrol, Nicorette DS, Nicotrol NS, ProStep, Nicotrol TD, Nicorelief

U.S. Cancer Deaths Decline Over Three Decades

Posted 24 Jan 2017 by Drugs.com

TUESDAY, Jan. 24, 2017 – While cancer death rates have dropped 20 percent overall in the United States since 1980, high death rates persist in pockets throughout the country, a new report finds. "Death rates differ dramatically between different types of cancers, and certain regions saw great progress in reducing cancer deaths and others fell behind," said lead researcher Dr. Christopher Murray. In all, 160 counties showed increases in cancer death rates between 1980 and 2014, noted Murray, director of the Institute for Health Metrics and Evaluation at the University of Washington in Seattle. For example, lung cancer kills more people in the United States than any other cancer, but death rates are more than 20 times higher in some parts of the country than others, he said. "Fewer Americans smoke today than in previous decades, but parts of the South and many rural areas still show high ... Read more

Related support groups: Cancer, Smoking, Breast Cancer, Smoking Cessation, Prostate Cancer, Nicotine, Lung Cancer, Non-Small Cell Lung Cancer, Nicorette, Nicoderm CQ, Nicotrol Inhaler, Commit, Habitrol, Nicorette DS, Nicotrol NS, ProStep, Nicotrol TD, Nicorelief

Exercise Rates Often Decline After Cancer Diagnosis

Posted 24 Jan 2017 by Drugs.com

MONDAY, Jan. 23, 2017 – Exercise can help cancer patients cope with their treatment, but as many as 75 percent reduce their physical activity after diagnosis, a new study finds. Getting motivated to exercise can be difficult when faced with a serious illness. And along with the fatigue and pain associated with cancer treatment, many patients may give up exercising, the study authors said. "We have about 25 million cancer survivors in the United States, and there is mounting evidence that suggests that physical activity and exercise improve many outcomes in patients with cancer," said lead researcher Dr. Jun Mao. He's chief of integrative medicine service at Memorial Sloan Kettering Cancer Center in New York City. These outcomes include a better quality of life and physical function and, potentially, survival, he noted. Many patients feel that being sick and receiving chemotherapy are ... Read more

Related support groups: Cancer, Fatigue, Breast Cancer, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer

Many With Advanced Lung Cancer Don't Get Treatments That Might Help

Posted 20 Jan 2017 by Drugs.com

FRIDAY, Jan. 20, 2017 – Many U.S. patients with late-stage lung cancer do not receive treatments that could prolong their lives, a new study finds. Researchers at the University of California, Davis Comprehensive Cancer Center analyzed 1998-2012 data from the U.S. National Cancer Database. They found that more than one in every five patients with non-small cell lung cancer (NSCLC) – by far the leading form of the disease – did not undergo any treatment. That included chemotherapy, radiotherapy or surgery, the researchers said. Many of the untreated patients were women, elderly, minorities, low-income and uninsured, according to the research team. The researchers found that the number of untreated patients with late-stage NSCLC even rose slightly during the study period. The reasons why some patients went untreated remain unclear, the researchers said. "We were able to identify a ... Read more

Related support groups: Surgery, Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Bronchogenic Carcinoma, Merkel Cell Carcinoma, Malignant Pleural Effusion

Delaying Chemo After Lung Cancer Surgery? Better Late Than Never

Posted 6 Jan 2017 by Drugs.com

FRIDAY, Jan. 6, 2017 – Lung cancer chemotherapy that's been delayed due to slow recovery from surgery can still provide real benefit to patients, a new study suggests. The study involved thousands of patients with non-small-cell lung cancers (NSCLC), which comprise about 90 percent of all lung tumors. Lung cancer remains the leading cancer killer in the United States. As the study authors explained, chemotherapy is a standard part of treatment for people who've already had surgery to treat tumors that are larger than 4 centimeters (about 1.5 inches) or that have spread to the lymph nodes. Typically, this post-surgical chemotherapy begins within six weeks of the surgery. However, not all patients are able to tolerate chemotherapy so quickly after their operation, including those who develop surgical complications. So, a team led by Dr. Daniel Boffa, from the Yale School of Medicine, ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Bronchogenic Carcinoma

Page 1 2 3 ... Next

Ask a Question

Further Information

Related Condition Support Groups

Lung Cancer

Related Drug Support Groups

methotrexate, Tarceva, Avastin, Taxol, Opdivo, Taxotere, Xalkori, Keytruda, cisplatin, view more... cyclophosphamide, capecitabine, Gemzar, paclitaxel, Iressa, nivolumab, gemcitabine, docetaxel, Tecentriq, Alimta, erlotinib, Cyramza, gefitinib, Abraxane, pembrolizumab, bevacizumab, crizotinib, Platinol, Navelbine, Gilotrif, vinorelbine, afatinib, amifostine, ramucirumab, alectinib, Alecensa, osimertinib, Tagrisso, Trexall, pemetrexed, cetuximab, Methotrexate LPF Sodium, Zykadia, Alunbrig, Portrazza, Ethyol, necitumumab, ceritinib, porfimer, paclitaxel protein-bound, atezolizumab, brigatinib, Platinol-AQ, Folex PFS, Photofrin, Onxol, Docefrez